The glycoPEGylated FGF21 analogue, pegozafermin, is generally well tolerated and associated with clinically meaningful reductions in liver fat, measures of liver function, and circulating lipids. These are the recent findings of a Phase 1b/2a double-blind, placebo-controlled, multiple-ascending-dose study of pegozafermin (3, 9, 18, or 27 mg once weekly; 18 or 36 mg once every 2 […]
Genetic testing for pancreatitis risk
Genetic testing may help identify patients with hypertriglyceridemia who are at greatest risk of developing pancreatitis and may benefit from novel triglyceride-lowering therapies, US researchers have concluded.
PROMINENT trial misses primary endpoint
Newly published results of the PROMINENT trial have shown that the SPPARα modulator, pemafibrate, affects a range of plasma lipid levels in patients with type 2 diabetes and mild-to-moderate hypertriglyceridemia (fasting median 271 mg/dL), but does not reduce cardiac events.
REDUCE-IT biomarker data raise more questions than answers
REDUCE-IT trial participants allocated to icosapent ethyl had minimal changes in biomarkers associated with atherosclerotic disease, a new sub-study has shown. In contrast, there were increases in biomarker levels in those allocated to the mineral oil used as placebo in the trial. At baseline, median levels of each biomarker were similar in REDUCE-IT participants randomly […]
Elevated remnant cholesterol aids heart disease prediction
Very elevated (>75th percentile) non-fasting REM-C or non-fasting TG deserve further evaluation as a potentially valuable modifier of atherosclerotic cardiovascular disease risk. Replication of current findings could potentially improve the care of patients at risk of ischaemic events.
NICE predicts hundreds of thousands to benefit from new icosapent ethyl guidance
New guidance about the use of icosapent ethyl (Vazkepa) for reducing cardiovascular (CV) risk, issued by the National Institute for Health and Care Excellence (NICE), is expected to benefit around 425,000 people in England treated on the country’s free National Health Service (NHS). NICE has recommended icosapent ethyl as an option for reducing the risk of CV events (eg. myocardial infarction and stroke) in adults.